arrow
P

Pinato, David J.

imperial college london
H指数:0
被引数:2

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

经动脉化疗栓塞治疗肝细胞癌后派姆单抗的安全性和初步疗效: PETAL Ib期研究

2024-04-053
OAAI
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

癌症患者的2型糖尿病和免疫检查点阻断的疗效结果

2023-06-0125
OA
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries

免疫检查点抑制剂治疗和癌症患者SARS-CoV-2感染的结果: OnCovid和esmo-cocare注册中心的联合分析

2022-11-305
OAAI
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study
2022-06-1635
OAAI
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry

新型冠状病毒肺炎后遗症和宿主促炎反应: 来自OnCovid注册表的分析

2022-04-1318
OAAI
Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.

经动脉化疗栓塞作为肝细胞癌免疫原性细胞死亡的局部区域诱导剂: 免疫治疗的意义。

2021-09-30106
OAAI
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score

系统性促炎反应可确定患有SARS-CoV-2感染不良后果的癌症患者: OnCovid炎症评分

2021-03-2225
OAAI
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
2020-10-0723
OAAI
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
2020-08-3149
OAAI
First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer
2014-11-3034
OAAI